This Week in Dermatology — Sep 4, 2026

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease therapeutics — from a new interleukin-36 antibody in pustular psoriasis to long-term JAK inhibition in eczema — plus consensus and guideline documents that tell you what to do when standard care fails, and a cluster of cutaneous oncology papers on melanoma, transplant skin cancer, and rare tumours. Let's dive in.

We start with new drug data in inflammatory skin disease, and the standout is in generalized pustular psoriasis. In the British Journal of Dermatology, Yang and colleagues report a multicentre, double-blind, placebo-controlled phase 2 trial in China of recibokibart, a humanised antibody against the interleukin-36 receptor, given as a single intravenous 1050 milligram dose during an acute flare [1]. Thirty-three patients were randomised two to one. At day eight, the primary endpoint — a physician global assessment pustulation sub-score of zero or one — was reached by about 86 percent of the recibokibart group compared with roughly 9 percent on placebo, an absolute difference of about 77 percentage points. Just over half of treated patients had complete pustule clearance in that first week, improvement was visible as early as 24 hours, and by week four close to three quarters OF PATIENTS had achieved a 75 percent reduction in the pustular psoriasis area and severity index. Adverse events included hypoproteinaemia, hypertriglyceridaemia and pruritus. Two caveats matter for interpretation: this is a small trial of 33 patients, and everything after day eight includes patients who crossed into open-label drug, so the durability data are descriptive rather than controlled. Still, this is a second interleukin-36 pathway antibody showing that a single infusion can abort a pustular flare within days, which reinforces that generalized pustular psoriasis should now be treated as a targeted-therapy disease rather than a steroid-and-retinoid improvisation.

Staying with inflammatory disease, the Journal of the European Academy of Dermatology and Venereology brings 52-week data on ivarmacitinib, an oral JAK1 inhibitor, in moderate-to-severe atopic dermatitis [2]. Of 336 randomised patients aged 12 to 75, 258 completed the year. Among those originally assigned to active drug, roughly four in ten reached a clear or almost-clear investigator global assessment at week 52, about 61 percent on the 4 milligram dose and 56 percent on the 8 milligram dose reached EASI-75, and itch responses were around 60 percent at the lower dose and 45 percent at the higher one. Treatment-emergent adverse events were common — around 85 to 88 percent of patients — but mostly upper respiratory infections, COVID, and raised creatine phosphokinase, with serious events in about one in twenty. The authors are appropriately restrained: there was no placebo control after week 16, so these long-term numbers are descriptive. The practical point is maintenance of effect at one year without a new safety signal, and the interesting wrinkle is that the higher dose did not deliver better outcomes at 52 weeks.

Contrast that with a trial where the primary endpoint was simply not met. In the Journal of the American Academy of Dermatology, Mathur and colleagues report NIKAIA-1, a 12-week randomised placebo-controlled study of nemolizumab, an interleukin-31 receptor antibody, in 258 haemodialysis patients with chronic kidney disease-associated pruritus [3]. Neither the 30 nor the 60 milligram dose significantly beat placebo on the proportion achieving a four-point drop in worst-itch score at week 12 — about 48 percent at the higher dose versus roughly 32 percent on placebo, which did not reach statistical significance. There were secondary signals: itch-related quality of life improved on the higher dose, and at week four about a quarter of nemolizumab patients hit the four-point itch threshold versus only about 7 percent on placebo. Safety was comparable across groups. But the honest read is a negative trial, with the placebo response in uraemic pruritus once again proving formidable. Do not extrapolate nemolizumab's prurigo nodularis performance to your dialysis patients.

The second theme this week is consensus guidance for the patient who isn't getting better. JAMA Dermatology publishes a three-round Delphi consensus from Gregoire and colleagues, involving 31 United States-based alopecia areata experts, on treating adults with severe disease [4]. Oral JAK inhibitors emerged as the primary long-term therapy for all patients, with dupilumab endorsed as an alternative for those with comorbid atopy. Supplemental agents that reached the 70 percent agreement threshold included oral and topical minoxidil, intralesional, oral and high-potency topical corticosteroids, and topical JAK inhibitors and prostaglandins for site-specific use such as brows and lashes, alongside a recommendation that patient support resources be offered as part of care. This is expert opinion, not trial evidence, and it explicitly excludes children, pregnant patients and mild-to-moderate disease — but it is exactly the kind of document that helps in a payer appeal.

Alongside that, the Journal of the American Academy of Dermatology publishes a GRADE-based Good Practice Statement from Sidbury and colleagues on the diagnostic workup of adults with presumed atopic dermatitis that is refractory to optimised treatment [5]. The core message is that when an adult eczema patient fails good therapy, the diagnosis itself deserves reassessment — misdiagnosis or a concomitant condition such as cutaneous T-cell lymphoma, contact allergy, or a primary immunodeficiency may be the reason. The workgroup is candid that direct empirical evidence for any specific workup strategy is lacking, so this rests on indirect evidence and consensus. Think of it as permission, and prompting, to stop escalating biologics and instead re-biopsy and patch test.

Our third theme is cutaneous oncology, where this week's message is mostly about uncertainty. In JEADV, Weitemeyer and colleagues used nationwide Danish data to ask whether adjuvant anti-PD-1 therapy actually changes survival in resected stage III melanoma, comparing 450 patients diagnosed before implementation with 552 after [6]. At the population level, there was no difference in five-year overall survival or melanoma-specific mortality. In a propensity-matched analysis of 279 pairs, treated patients did have higher five-year overall survival — about 80 percent versus 72 percent, roughly a third lower risk of death — but melanoma-specific mortality was inconclusive, and the authors note that only large effects were detectable with the events available. The uncomfortable possibility that melanoma-specific mortality did not clearly move should temper how confidently we counsel patients about adjuvant benefit, particularly as neoadjuvant strategies mature.

Also in JAMA Dermatology, Neff and colleagues address a nosologic question with practical teeth: is pleomorphic dermal sarcoma a sarcoma or a cutaneous carcinoma [7]? Using a 447-gene sequencing assay on nine pleomorphic dermal sarcomas, 15 metastatic cutaneous squamous cell carcinomas and 25 soft-tissue sarcomas, they found tumour mutational burden of about 45 in the dermal sarcomas and about 54 in squamous cell carcinoma — statistically indistinguishable from each other — versus about 4 in soft-tissue sarcoma. Every pleomorphic dermal sarcoma and every squamous cell carcinoma carried an ultraviolet signature; no soft-tissue sarcoma did. On principal component analysis the two cutaneous tumours clustered completely on top of each other. With only nine cases from a single centre this is hypothesis-generating, but it argues that pleomorphic dermal sarcoma should be managed on cutaneous carcinoma lines — including consideration of checkpoint inhibition.

A two-part review in the Journal of the American Academy of Dermatology from Kimball and colleagues covers human papillomavirus-associated cutaneous malignancy in solid organ transplant recipients, with part one on identification and part two on management and prevention [8][9]. The practical instructions are risk-stratified screening using tools such as SUNTRAC, surgical excision with complete margin assessment for high-risk tumours, radiotherapy and checkpoint inhibitors in selected cases, and — importantly — strong advocacy for human papillomavirus vaccination before transplantation, a conversation dermatologists are well placed to have. Rounding out the oncology set, Pediatric Dermatology reports a Turkish national cohort of 133 children with mycosis fungoides [10]. Median diagnostic delay was 18 months, most children presented with stage IA disease, and early response occurred in about nine in ten. But relapse affected close to a third OF PATIENTS, usually within the first year, and body surface area under 10 percent predicted better early response while older age at diagnosis predicted worse — a clear argument for long-term surveillance even after apparent clearance.

If you only have time for one paper this week, make it the recibokibart phase 2 trial in the British Journal of Dermatology [1]. Generalized pustular psoriasis flares are a dermatologic emergency, and a single infusion clearing pustules within 24 to 48 hours in the great majority of patients changes how you should plan for the next patient who arrives on your inpatient service.

Here are the key takeaways from this week in Dermatology. First, interleukin-36 receptor blockade continues to deliver rapid flare control in generalized pustular psoriasis, though the evidence base remains small [1]. Second, oral JAK1 inhibition with ivarmacitinib maintains eczema responses to one year, with no advantage to the higher dose [2]. Third, nemolizumab missed its primary endpoint in dialysis-associated pruritus — a negative trial, despite a rapid early itch signal [3]. Fourth, when adult atopic dermatitis fails optimised therapy, reassess the diagnosis before escalating [5], and for severe alopecia areata, oral JAK inhibitors are now the consensus backbone with dupilumab as an atopic-comorbidity alternative [4]. Fifth, in oncology, adjuvant anti-PD-1 in stage III melanoma showed a matched-analysis survival benefit but no clear population-level or disease-specific effect [6]; pleomorphic dermal sarcoma looks genetically like cutaneous squamous cell carcinoma [7]; and paediatric mycosis fungoides relapses in nearly a third of children within the first year, so keep them under surveillance [10].

That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.